Running head: ADVANCED PHARMACOLOGY
Date of Submission
Erythromycin Lactobionate Injection
The drug chosen in FDA’s list is Erythromycin lactobionate injection. Erythromycin has
existed for over 50 years and its derivatives have been used to treat pathogens like pneumococci
and streptococci. Erythromycin has an inhibitive effect on these pathogens thereby reducing the
impact of their damage on the human body. The drug Erythromycin is insoluble and therefore
cannot be ingested easily into the body system. For this, reason soluble salts like erythromycin
lactobionate were derived to enable the ingestion of erythromycin through injections. However,
the FDA has reported a shortage of the drug. This could raise some negative implications on
patients who have been prescribed the drug.
Among the negative implications could be brought about by the shortage of this drug is
low erythromycin levels in the serum. This is plausible for patients who cannot take
erythromycin orally. This increases the concentration and activity of bacteria in the patient’s
body which could worsen the health of the patient. Shortage of erythromycin could also worsen
the effects of respiratory infections among patients. Erythromycin is used to contain the severity
of respiratory infections. The shortage of the drug also gives time for bacteria and other
pathogens to grow some resistance against erythromycin. Therefore, at the time of
administration, the drug may not be effective as expected. Other negative implications include
worsening of skin infections for the patients who cannot take oral medication. There could also
arise soft tissue infections which could be as a result of high and uncontrolled growth of bacteria
in the body.
Despite the shortage, other alternatives have been developed to aid in the treatment of
streptococci and pneumococci. One alternative is erythromycin taurate which works the same
way as the erythromycin lactobionate. This alternative is made from erythromycin and taurine
which is an essential amino acid that used in the treatment of respiratory diseases and epilepsy.
Erythromycin taurate is made through the acid base reaction of erythromycin base and tauric
acid. The taurate derivative differs from the lactobionate in that it is highly soluble in organic
solvents like methanol and ethanol. Theref...